Synergy between ABT-737 and two other BCRABL inhibitors, imatinib and nilotinib, that are used in the treatment of CML has also been reported [68-71]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.